Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7474 pages
Showing 301 - 350T-DXd in HER2-Overexpressing Unresectable or Metastatic NSCLC
As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer (NSCLC) cohorts of the phase II DESTINY-Lung01 trial show activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in this setting. Prior ...
GU and GI Symptoms With Postprostatectomy Radiotherapy for Prostate Cancer
As reported in JAMA Oncology by Mark K. Buyyounouski, MD, MS, and colleagues, the phase III NRG-GU003 trial showed noninferiority of hypofractionated postprostatectomy radiotherapy (HYPORT) vs conventionally fractionated postprostatectomy radiotherapy (COPORT) for genitourinary (GU) and...
NSCLC: Neoadjuvant Chemoimmunotherapy vs Neoadjuvant Chemotherapy
In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better outcomes than neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC). Study Details A search of published studies reported...
Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Domenica Lorusso, MD, PhD, and colleagues, the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial has shown that the addition of pembrolizumab to chemoradiotherapy improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced...
Eligibility for and Prevalence of Lung Cancer Screening in the United States in 2022
In a study reported in a research letter in JAMA Network Open, Henderson et al identified prevalence of lung cancer screening in the United States in 2022 using U.S. Preventive Services Task Force (USPSTF) 2021 and 2013 recommendations for screening eligibility. The USPSTF 2013 guidelines...
Inotuzumab Ozogamicin for Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, inotuzumab ozogamicin (Besponsa) was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting Efficacy Data Approval was based on findings in the ITCC-059 trial (ClinicalTrials.gov...
Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved...
Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma
On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. This represents the first U.S. ...
Early Breast Cancer: Nurse-Led Follow-up Intervention and Quality of Life After Treatment
In a Danish single-institution phase III trial (MyHealth) reported in the Journal of Clinical Oncology, Saltbæk et al found that nurse-led individualized follow-up was associated with significantly better breast cancer–specific quality of life compared with usual care after completion of primary...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...
Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adjuvant mFOLFOX6 (modified fluorouracil, leucovorin, and...
Endoscopic Screening and Esophageal Cancer Incidence and Mortality
In an analysis of 9-year outcomes of a Chinese trial (ESECC) reported in the Journal of Clinical Oncology, Liu et al found that endoscopic screening for esophageal cancer was associated with numeric benefit vs no screening in terms of the incidence of esophageal cancer and esophageal cancer–related ...
Stopping TKI Treatment in Chronic Myeloid Leukemia
In a report in the Journal of Clinical Oncology, Francois-Xavier Mahon, MD, PhD, and colleagues provided the final analysis of the European Stop Kinase Inhibitors (EURO-SKI) study. The trial evaluated the effect of stopping tyrosine kinase inhibitor (TKI) treatment in patients with chronic myeloid...
Integrated Screening and Stepped Collaborative Care Intervention: Effect on Health-Related Quality of Life in Patients With Cancer
In a phase III trial reported in The Lancet, Jennifer Steel, PhD, and colleagues found that an integrated screening and stepped collaborative care intervention (CARES) improved health-related quality of life vs standard of care in patients with cancer. Study Details In the study, 459 patients from ...
Early Breast Cancer: Adding Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy
As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of adjuvant ribociclib to a nonsteroidal aromatase inhibitor (NSAI) in patients with...
Adjuvant Nivolumab in Stage IIB/C Melanoma
On October 13, 2023, nivolumab was approved for adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.1 Supporting Efficacy Data Approval was based on findings in the double-blind CheckMate 76K trial (ClinicalTrials.gov identifier NCT04099251), in which...
Lifileucel for Unresectable or Metastatic Melanoma
On February 16, 2024, lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, was granted accelerated approval for adults with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody, and if BRAF V600 mutation–positive, a BRAF inhibitor with or without a...
Enfortumab Vedotin-ejfv Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
On December 15, 2023, enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) was approved for patients with locally advanced or metastatic urothelial cancer.1,2 Supporting Efficacy Data Approval was based on findings in the open-label EV-302 trial (ClinicalTrials.gov...
Erdafitinib for Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, 2024, erdafitinib (Balversa) was approved for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by a U.S. Food & Drug Administration–approved companion diagnostic test, whose disease has progressed on or...
FLT3-ITD–Mutated AML: Gilteritinib in Posttransplantation Maintenance
In the phase III MORPHO trial reported in the Journal of Clinical Oncology, Mark J. Levis, MD, PhD, and colleagues found that the FLT3 inhibitor gilteritinib showed activity as post–allogeneic hematopoietic cell transplantation (HCT) maintenance among patients with FLT3-ITD–mutated acute myeloid...
Racial/Ethnic Differences in Care Intensity at the End of Life for Patients With Lung Cancer
In a study reported in the Journal of Clinical Oncology, Rodriguez et al identified racial/ethnic differences in intensity of end-of-life care among patients in California who died from lung cancer between 2005 and 2018. Study Details The study used data from the California Cancer Registry linked...
Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia
As reported in The Lancet Oncology by Kater et al, the phase IIIb VENICE-1 trial has shown activity of venetoclax monotherapy in adult patients with relapsed or refractory chronic lymphocytic leukemia, including those with prior B-cell receptor–associated kinase (BCR) inhibitor treatment. Study...
Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma.1 Supporting Efficacy Data Approval was based on the open-label NAPOLI 3...
Effect of HER2 Gene–Expression Levels on Outcomes in Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Battaglin et al, an analysis from the phase III CALGB/SWOG 80405 trial of first-line chemotherapy plus bevacizumab or cetuximab in patients with metastatic colorectal cancer showed differences in outcomes according to HER2 gene–expression status....
Localized Prostate Cancer: Association of PSA Nadir Within 6 Months of Radiotherapy With Outcomes
In a study reported in the Journal of Clinical Oncology, Kwak et al found that prostate-specific antigen (PSA) levels ≥ 0.1 ng/mL within 6 months after completion of radiotherapy were prognostic for poorer outcomes in patients with localized prostate cancer who did or did not also receive...
Repotrectinib for ROS1 Fusion–Positive Advanced NSCLC
On November 15, 2023, repotrectinib (Augtyro) was approved for locally advanced or metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC).1 This is the first U.S. Food and Drug Administration approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1...
Osimertinib With Chemotherapy for EGFR-Mutated NSCLC
On February 16, 2024, osimertinib (Tagrisso) was approved by the U.S. Food and Drug Administraton (FDA) with pemetrexed and platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with tumors having EGFR exon 19 deletions or exon 21 L858R...
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
In the BLUE-C study—reported in The New England Journal of Medicine—Imperiale et al found that a next-generation multitarget stool DNA test showed high sensitivity for colorectal cancer and high specificity for advanced neoplasia compared with colonoscopy screening. Study Details The U.S....
Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in the Journal of Clinical Oncology by Jason J. Luke, MD, FACP, and colleagues, the final prespecified analysis of distant metastasis–free survival in the phase III KEYNOTE-716 trial showed continued benefit with adjuvant pembrolizumab vs placebo in patients with resected stage IIB or...
Performance of cfDNA Blood-Based Test for Colorectal Cancer Screening
In the ECLIPSE study—reported in The New England Journal of Medicine—Chung et al found that a cell-free DNA (cfDNA) blood-based test had high sensitivity for colorectal cancer and high specificity for advanced neoplasia in colorectal cancer screening compared with colonoscopy. Study Details The...
Localized or Advanced Prostate Cancer: Short- or Longer-Term Relugolix Plus Radiotherapy
In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. Study Details The analysis...
SABR for Patients With Primary Kidney Cancer Not Undergoing Resection
In a phase II study (FASTRACK II) reported in The Lancet Oncology, Shankar Siva, MBBS, PhD, and colleagues found that stereotactic ablative body radiotherapy (SABR) was effective in patients with primary kidney cancer who did not undergo resection. Study Details Seventy patients were enrolled in...
H pylori Infection: Risk of Colorectal Cancer and Colorectal Cancer–Related Mortality
In a study among U.S. veterans reported in the Journal of Clinical Oncology, Shah et al found that Helicobacter pylori infection was associated with an increased risk of colorectal cancer and cancer-related death; additionally, treated H pylori infection was associated with reduced cancer incidence ...
p16-Positive Oropharyngeal Cancer: Surrogate Endpoints for Overall Survival in Clinical Trials
In a retrospective review reported in The Lancet Oncology, Gharzai et al identified intermediate clinical endpoints that may serve as surrogates for overall survival in trials assessing definitive treatment of patients with p16-positive oropharyngeal squamous cell carcinoma. Study Details The...
Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor
As reported in The New England Journal of Medicine by Thomas Powles, MD, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody-drug conjugate enfortumab vedotin-ejfv and the PD-1 inhibitor pembrolizumab improved progression-free and overall survival vs...
SABR in Patients With Early NSCLC and Interstitial Lung Disease
In a study reported in JAMA Oncology, David A. Palma, MD, PhD, and colleagues found that stereotactic ablative radiotherapy (SABR) met criteria for efficacy and toxicity in patients with early non–small cell lung cancer (NSCLC) and interstitial lung disease (ILD). As stated by the investigators,...
Nab-sirolimus in Advanced Malignant Perivascular Epithelioid Cell Tumors: AMPECT Trial Final Analysis
As reported in the Journal of Clinical Oncology by Wagner et al, final analysis of the phase II AMPECT trial has shown a median duration of response of more than 3 years in patients with advanced malignant perivascular epithelioid cell tumors treated with nab-sirolimus. The primary analysis of the...
Cancer Prevalence in Europe as of 2020
In a study reported in The Lancet Oncology, De Angelis et al estimated the numbers of patients alive after a cancer diagnosis in Europe as of 2020. Study Details The study used data from the EUROCARE-6 study to estimate the prevalence of cancer in 29 European countries and the 27 countries in the ...
Metastatic Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Single-Agent Chemotherapy in Previously Treated Patients
As reported in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, and colleagues, final results of the phase III ASCENT trial showed continued superior progression-free and overall survival with sacituzumab govitecan-hziy, an anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug...
Sunitinib in Metastatic Progressive Pheochromocytomas and Paragangliomas
In a phase II trial (FIRSTMAPPP) reported in The Lancet, Eric Baudin, MD, and colleagues found that the multikinase inhibitor sunitinib was active in patients with metastatic progressive pheochromocytomas and paragangliomas. As stated by the investigators, “No randomized controlled trial has ever...
Immunotherapy Trials for Metastatic NSCLC: FDA Pooled Analysis
In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Bernardo Haddock Lobo Goulart, MD, and colleagues found that response rate and progression-free survival were only moderately correlated with overall survival in first-line immunotherapy trials for...
Patients With Biochemical Recurrence of Prostate Cancer: Ga-68–RM2 PET-MRI vs MRI Alone for Lesion Detection
In a single-center phase II/III imaging trial reported in The Lancet Oncology, Duan and colleagues found that gallium Ga-68–labeled RM2 (Ga-68–RM2) positron-emission tomography (PET)-magnetic resonance imaging (MRI) outperformed MRI alone in positive findings and number of lesions detected in...
Variations in Use of Radiotherapy in Patients With Newly Diagnosed Common Cancers
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al found wide interjurisdictional variation in the use of radiotherapy among patients with newly diagnosed common cancers in Norway, the United Kingdom, Canada, and Australia. Study Details The...
Fruquintinib in Refractory Metastatic Colorectal Cancer
On November 8, 2023, fruquintinib (Fruzaqla) was approved for adults with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if RAS wild-type and medically appropriate—an anti-EGFR therapy.1 Supporting...
Primary Tumor Resection Before Chemotherapy in Patients With Colon Cancer and Unresectable Metastases
In a pooled analysis reported in the Journal of Clinical Oncology, Rahbari et al found that primary tumor resection before chemotherapy did not extend survival compared with upfront chemotherapy in patients with colon cancer and unresectable metastases. Study Details The study involved data from...
Topical Diclofenac to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast or gastrointestinal cancer who were ...
Factors Associated With Myeloid Neoplasms Following CAR T-Cell Therapy
In an analysis reported in a research letter in JAMA Oncology, Gurney et al identified factors associated with an increased risk of myeloid neoplasms after chimeric antigen receptor (CAR) T-cell therapy. Study Details Investigators identified adults who received CAR T-cell therapy between June 2016 ...
Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Study Details...
Low-Risk Cervical Cancer: Pelvic Recurrence With Simple vs Radical Hysterectomy
As reported by Marie Plante, MD, and colleagues in The New England Journal of Medicine, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in terms of pelvic recurrence in women with low-risk cervical cancer. Simple hysterectomy was associated with a reduced...
